Scientists at the University of Pittsburgh School of Medicine (USA) have isolated the smallest biological molecule to date that, in animal models, neutralizes the new coronavirus, which causes the disease called Covid-19.
This molecule has been used to build a drug, known as Ab8, for potential use as a therapeutic and prophylactic against SARS-CoV-2. In fact, as reported by experts, whose work has been published in the journal “Cell”, is “very effective» To prevent and treat SARS-CoV-2 infection in mice and hamsters.
And, its small size not only increases its potential for diffusion in tissues to better neutralize the virus but also allows the drug to be administered by alternative routes, including inhalation. Furthermore, it does not bind to human cells, which is a ‘good sign» That it will not cause side effects in people.
“Ab8 not only has potential as a therapy for Covid-19, but it could also be used to prevent people from contracting coronavirus infections. The larger antibodies have worked against other infectious diseases and have been well-tolerated, giving us hope that it could be an effective treatment for patients with Covid-19 and for the protection of those who have never had the infection and they are not immune ”, the experts have pointed out.
Even at the lowest dose, they have observed, Ab8 decreased the amount of infectious virus in these mice by 10 times compared to their untreated counterparts. Furthermore, it was also effective in the treatment and prevention of SARS-CoV-2 infection in hamsters. Abound Bio, a newly formed company backed by UPMC, has licensed Ab8 for Worldwide Development.